Doctors are not safe with some patients.

Todays Updates

Weighing Bleeding Risk in Pulmonary Embolism, With Samantha Pettigrew, MD Samantha Pettigrew, MD

At CHEST 2026, Pettigrew reviewed STRATIFY and STORM-PE data, citing bleeding risk with low-dose alteplase and 90-day walk gains with thrombectomy.

AI and Emerging Technologies in COPD Care, With Jean Bourbeau, MD Jean Bourbeau, MD

At CHEST 2026, Jean Bourbeau, MD, said AI may support COPD diagnosis, remote monitoring, and posthospital care, though most tools still need validation.

Tozorakimab Sustains COPD Exacerbation Benefit to 2 Years: Henrik Watz, MD Henrik Watz, MD, PhD

Henrik Watz, MD, discusses 104-week OBERON, TITANIA, and PROSPERO data on tozorakimab in COPD presented at CHEST 2026.

Frespaciguat Misses 6MWD End Point in PH-COPD: Gabor Kovacs, MD, PhD Gabor Kovacs, MD, PhD

Gabor Kovacs, MD, PhD, discusses phase 2a INSIGNIA PH-COPD results for inhaled frespaciguat presented at CHEST 2026.

Ralinepag's Benefit Spans Broad PAH Population, With Jean Elwing, MD

TPIP Tolerable Over 2 Years in PH-ILD, With Colin Church, MBBS, PhD

TPIP's Efficacy Holds as PALM-ILD Advances, With Colin Church, MBBS, PhD

Todays Updates

Weighing Bleeding Risk in Pulmonary Embolism, With Samantha Pettigrew, MD Samantha Pettigrew, MD

At CHEST 2026, Pettigrew reviewed STRATIFY and STORM-PE data, citing bleeding risk with low-dose alteplase and 90-day walk gains with thrombectomy.

AI and Emerging Technologies in COPD Care, With Jean Bourbeau, MD Jean Bourbeau, MD

At CHEST 2026, Jean Bourbeau, MD, said AI may support COPD diagnosis, remote monitoring, and posthospital care, though most tools still need validation.

Tozorakimab Sustains COPD Exacerbation Benefit to 2 Years: Henrik Watz, MD Henrik Watz, MD, PhD

Henrik Watz, MD, discusses 104-week OBERON, TITANIA, and PROSPERO data on tozorakimab in COPD presented at CHEST 2026.

Frespaciguat Misses 6MWD End Point in PH-COPD: Gabor Kovacs, MD, PhD Gabor Kovacs, MD, PhD

Gabor Kovacs, MD, PhD, discusses phase 2a INSIGNIA PH-COPD results for inhaled frespaciguat presented at CHEST 2026.

Ralinepag's Benefit Spans Broad PAH Population, With Jean Elwing, MD

TPIP Tolerable Over 2 Years in PH-ILD, With Colin Church, MBBS, PhD

TPIP's Efficacy Holds as PALM-ILD Advances, With Colin Church, MBBS, PhD

Doctors are not safe with some patients.

Latest News

Biomarker to Bedside: Practical Approaches to HER2 Testing and Targeted Treatment in Gynecologic Cancers

From Pathways to Practice: Improving Outcomes for Veterans With Metastatic Hormone-Sensitive Prostate Cancer

Bladder Issues Linger in Kids Treated for Ureter Swelling

Precision Oncology in mHSPC: Translating Emerging Evidence Into Clinical Practice

Practical Implications of Targeted Therapies in mHSPC Care

Clinical Data and Expert Perspectives on Emerging Bispecific ADCs in Urothelial Carcinoma

Todays Updates

Weighing Bleeding Risk in Pulmonary Embolism, With Samantha Pettigrew, MD Samantha Pettigrew, MD

AI and Emerging Technologies in COPD Care, With Jean Bourbeau, MD Jean Bourbeau, MD

Tozorakimab Sustains COPD Exacerbation Benefit to 2 Years: Henrik Watz, MD Henrik Watz, MD, PhD

Frespaciguat Misses 6MWD End Point in PH-COPD: Gabor Kovacs, MD, PhD Gabor Kovacs, MD, PhD

Ralinepag's Benefit Spans Broad PAH Population, With Jean Elwing, MD

TPIP Tolerable Over 2 Years in PH-ILD, With Colin Church, MBBS, PhD

TPIP's Efficacy Holds as PALM-ILD Advances, With Colin Church, MBBS, PhD

Todays Updates

Weighing Bleeding Risk in Pulmonary Embolism, With Samantha Pettigrew, MD Samantha Pettigrew, MD

AI and Emerging Technologies in COPD Care, With Jean Bourbeau, MD Jean Bourbeau, MD

Tozorakimab Sustains COPD Exacerbation Benefit to 2 Years: Henrik Watz, MD Henrik Watz, MD, PhD

Frespaciguat Misses 6MWD End Point in PH-COPD: Gabor Kovacs, MD, PhD Gabor Kovacs, MD, PhD

Ralinepag's Benefit Spans Broad PAH Population, With Jean Elwing, MD

TPIP Tolerable Over 2 Years in PH-ILD, With Colin Church, MBBS, PhD

TPIP's Efficacy Holds as PALM-ILD Advances, With Colin Church, MBBS, PhD

Latest News

News All Time

Latest Clinical Data for Emerging Combination Strategies in mHSPC

Redefining MIBC Standards: Multidisciplinary Insights on Optimizing Immunotherapy-Based Combinations

Shaping the Future of Muscle-Invasive Bladder Cancer Treatment With the Integration of Immunotherapy and Multidisciplinary Care

Towards Personalized Treatment in mHSPC: Latest Evidence for Biomarker-Targeted Therapies and Multidisciplinary Toxicity Management

Advancing mHSPC Management: From Clinical Guidelines to Emerging Biomarker-Directed Therapies

Optimizing mHSPC Care: Integrating Novel Combination Therapies and the Strategies for Multidisciplinary Management

Personalized Decision-Making for Patients With Advanced HSPC

Too Much or Too Little Opioid Pain Relief May Drive Refills After Urologic Surgery

Durvalumab Plus BCG Cut Early Recurrence of High-Risk Bladder Cancer

Half of Patients With Post-BCG Bladder Cancer Achieve CR With Nonviral Gene Therapy

Low-Intensity Ultrasound Shatters Kidney Stones in 70% of SOUND Trial Patients

Major Complete Response Rate in Very High-Risk Bladder Cancer With Combo Treatment

Temporary Prostatic Urethra Expander for BPH/LUTS Shows Durable Results

Evidence Mounts for Darolutamide Plus ADT in Hormone-Sensitive Prostate Cancer

He Inserted a Cable in His Penis. 10 Years Later, He Needed Surgery.

Erectile Dysfunction May Predispose Older Men to Multiple Types of Substance Abuse

Recommended News For You

In patients with prostate cancer, second-generation antiandrogens may worsen fatigue, falls, and cognitive decline.

Ultrasound bras; HPV and thyroid cancer; language minimizing adverse events.

Climate change is expected to increase the number of suicide deaths

Tafasitamab-Based Combination Boosts PFS in Relapsed/Refractory Follicular Lymphoma

The diamonds that could find cancer

NIH research cuts leave cancer patient facing hard choice

Scientists call into question safety of potential new anticancer treatment

Recommended Articles For You

Understanding Fibrosarcoma: What You Need to Know

Preventing Venous Thromboembolism During Hematologic Cancer Care

Understanding Odontogenic Keratocyst: Symptoms, Causes, and Treatments from Dental Experts

Precision Oncology Using Tumor Evolutionary Trajectory Modeling

Whats more on Hidoc Dr.

Medical Updates

KOL Videos

Surveys

Events

Featured News

Featured Articles

Featured Events

Featured KOL Videos

Quick Links

Verification

Welcome to Hidoc Dr.